Celgene (NASDAQ: CELG), Ameristar Casinos (NASDAQ: ASCA), Brown & Brown Inc. (NYSE: BRO), Alon USA Energy, Inc. (NYSE: ALJ), Infospace Inc. (NASDAQ: INSP) and Alaska Air (NYSE: ALK) ratings and price targets.
Celgene (CELG) had its “buy” rating reiterated by Jefferies Group (NYSE:JEF). They have a price target of $78.00 on the firm.
Ameristar Casinos (ASCA) is now covered by ISI Group. They have a “buy” rating and a price target of $24.00 on the firm.
Brown & Brown Inc. (BRO) is now covered by Deutsche Bank (NYSE:DB). They have a “buy” rating and a price target of $27.00 on the firm.
Alon USA Energy, Inc. (ALJ) was downgraded by Zacks Investment Research from a “neutral” rating to an “underperform” rating.
Infospace Inc. (INSP) had its price target raised by Benchmark Co. from $11.00 to $14.00. They have a “buy” rating on the firm.
Alaska Air (ALK) was downgraded by Deutsche Bank from a “buy” rating to a “hold” rating. They have a $80.00 price target on the firm.
Showing posts with label Celgene. Show all posts
Showing posts with label Celgene. Show all posts
Tuesday, January 10, 2012
Wednesday, January 4, 2012
Celgene (CELG) (CAVM) (CSTR) (CCI) (MMM) (NATI) Ratings, Price Targets
Celgene (NASDAQ: CELG), Cavium Networks, Inc. (NASDAQ: CAVM), Coinstar (NASDAQ: CSTR), Crown Castle (NYSE: CCI), 3M Company (NYSE: MMM) and National Instruments Corp. (NASDAQ: NATI) ratings and price targets.
Cavium Networks, Inc. (CAVM) is now covered by Roth Capital. They have a “buy” rating on the firm.
Celgene (CELG) had its “outperform” rating reiterated by Robert W. Baird.
Coinstar (CSTR) had its “overweight” rating reiterated by Piper Jaffray (NYSE:PJC).
Crown Castle (CCI) is now covered by Stifel Nicolaus. They have a “buy” rating and a price target of $55.00 on the firm.
3M Company (MMM) had its price target raised by Jefferies Group (NYSE:JEF) to $94.00.
National Instruments Corp. (NATI) had its price target lowered by JPMorgan Chase & Co. (NYSE:JPM) to $32.00.
Cavium Networks, Inc. (CAVM) is now covered by Roth Capital. They have a “buy” rating on the firm.
Celgene (CELG) had its “outperform” rating reiterated by Robert W. Baird.
Coinstar (CSTR) had its “overweight” rating reiterated by Piper Jaffray (NYSE:PJC).
Crown Castle (CCI) is now covered by Stifel Nicolaus. They have a “buy” rating and a price target of $55.00 on the firm.
3M Company (MMM) had its price target raised by Jefferies Group (NYSE:JEF) to $94.00.
National Instruments Corp. (NATI) had its price target lowered by JPMorgan Chase & Co. (NYSE:JPM) to $32.00.
Wednesday, December 14, 2011
Celgene (CELG) (SGEN) (SIGI) (SIX) (BGG) (BX) Ratings, Price Targets
Celgene (CELG), Seattle Genetics, Inc. (SGEN), Selective Insurance Group (SIGI), Six Flags Entertainment Corp. (SIX), Briggs & Stratton Corp. (BGG) and The Blackstone Group L.P. (BX) ratings and price targets.
Needham & Company reiterated its “Buy” rating on Seattle Genetics, Inc. (SGEN).
Zacks Investment Research upgraded Selective Insurance Group (SIGI) from an “Underperform” rating to a “Neutral” rating.
KeyBanc initiated coverage on Six Flags Entertainment Corp (SIX). They placed a “Hold” rating on the company.
Zacks Investment Research downgraded Briggs & Stratton Corp. (BGG) from an “Outperform” rating to a “Neutral” rating.
Jefferies (NYSE:JEF) reiterated its “Buy” rating on The Blackstone Group L.P. (BX). They have a price target of $17.00 on the company.
Jefferies reiterated its “Buy” rating on Celgene (CELG). They have a price target of $72.00 on the company.
Needham & Company reiterated its “Buy” rating on Seattle Genetics, Inc. (SGEN).
Zacks Investment Research upgraded Selective Insurance Group (SIGI) from an “Underperform” rating to a “Neutral” rating.
KeyBanc initiated coverage on Six Flags Entertainment Corp (SIX). They placed a “Hold” rating on the company.
Zacks Investment Research downgraded Briggs & Stratton Corp. (BGG) from an “Outperform” rating to a “Neutral” rating.
Jefferies (NYSE:JEF) reiterated its “Buy” rating on The Blackstone Group L.P. (BX). They have a price target of $17.00 on the company.
Jefferies reiterated its “Buy” rating on Celgene (CELG). They have a price target of $72.00 on the company.
Thursday, August 18, 2011
First Solar (FSLR) (WABC) (HD) (CELG) (PDCO) (CGV) Price Targets Changed
First Solar, Inc. (NASDAQ: FSLR), WestAmerica Bancorp. (NASDAQ: WABC), Home Depot (NYSE: HD), Celgene (NASDAQ: CELG), Patterson Companies Inc (NASDAQ: PDCO) and CGG Veritas (NYSE: CGV) had their price targets adjusted by analysts.
WestAmerica Bancorp (WABC) had its price target lowered by RBC Capital from $52.00 to $46.00. They have a “Sector Perform” rating on the company.
First Solar, Inc. (FSLR) had its price target lowered by Auriga from $168.00 to $154.00. They have a “Buy” rating on the company.
Home Depot (HD) had its price target raised by UBS AG (NYSE:UBS) from $38.00 to $40.00. They have a “Buy” rating on the company.
Celgene (CELG) had its price target raised by Summer Street Research from $67.00 to $71.00. They have a “Buy” rating on the company.
Patterson Companies Inc. (PDCO) had its price target lowered by UBS AG from $37.00 to $32.00. They have a “Neutral” rating on the company.
CGG Veritas (CGV) had its price target lowered by RBC Capital from $29.00 to $22.50. They have an “Outperform” rating on the company.
WestAmerica Bancorp (WABC) had its price target lowered by RBC Capital from $52.00 to $46.00. They have a “Sector Perform” rating on the company.
First Solar, Inc. (FSLR) had its price target lowered by Auriga from $168.00 to $154.00. They have a “Buy” rating on the company.
Home Depot (HD) had its price target raised by UBS AG (NYSE:UBS) from $38.00 to $40.00. They have a “Buy” rating on the company.
Celgene (CELG) had its price target raised by Summer Street Research from $67.00 to $71.00. They have a “Buy” rating on the company.
Patterson Companies Inc. (PDCO) had its price target lowered by UBS AG from $37.00 to $32.00. They have a “Neutral” rating on the company.
CGG Veritas (CGV) had its price target lowered by RBC Capital from $29.00 to $22.50. They have an “Outperform” rating on the company.
Monday, August 1, 2011
Avon (AVP) (CELG) (DDD) (DRIV) (GGG) (MXIM) Price Targets Adjusted
Avon Products, Inc. (NYSE: AVP), Celgene (NASDAQ: CELG), 3D Systems Co. (NYSE: DDD), Digital River, Inc. (NASDAQ: DRIV), Graco Inc. (NYSE: GGG) and Maxim Integrated Products Inc. (NASDAQ: MXIM) price targets adjusted by analysts.
Avon Products, Inc. (AVP) had its price target lowered by RBC Capital from $33.00 to $30.00. They have a “Sector Perform” rating on the company.
Celgene (CELG) had its price target raised by RBC Capital from $58.00 to $62.00. They have a “Sector Perform” rating on the company.
3D Systems Co. (DDD) had its price target lowered by Needham & Company from $28.00 to $26.00. They have a “Buy” rating on the company.
Digital River, Inc. (DRIV) had its price target lowered by FBR Capital from $41.00 to $35.00. They have an “Outperform” rating on the company.
Graco Inc. (GGG) had its price target lowered by Goldman Sachs (NYSE:GS) to $47.50. They have a “Sell” rating on the company.
Maxim Integrated Products Inc. (MXIM) had its price target raised by Stifel Nicolaus from $28.00 to $30.00. They have a “Buy” rating on the company.
Avon Products, Inc. (AVP) had its price target lowered by RBC Capital from $33.00 to $30.00. They have a “Sector Perform” rating on the company.
Celgene (CELG) had its price target raised by RBC Capital from $58.00 to $62.00. They have a “Sector Perform” rating on the company.
3D Systems Co. (DDD) had its price target lowered by Needham & Company from $28.00 to $26.00. They have a “Buy” rating on the company.
Digital River, Inc. (DRIV) had its price target lowered by FBR Capital from $41.00 to $35.00. They have an “Outperform” rating on the company.
Graco Inc. (GGG) had its price target lowered by Goldman Sachs (NYSE:GS) to $47.50. They have a “Sell” rating on the company.
Maxim Integrated Products Inc. (MXIM) had its price target raised by Stifel Nicolaus from $28.00 to $30.00. They have a “Buy” rating on the company.
Monday, May 2, 2011
Ratings on (AIQ) (AXL) (BPFH) (BTUI) (CELG) Reiterated
Ratings on Alliance HealthCare Services, Inc. (NYSE: AIQ), American Axle & Manufacturing Holdings Inc (NYSE: AXL), Boston Private Financial Holdings Incorporated (NASDAQ: BPFH), BTU International (NASDAQ: BTUI) and Celgene (NASDAQ: CELG) reiterated by analysts.
Morgan Keegan reiterated a “market perform” rating on Alliance HealthCare Services, Inc. (AIQ).
Jefferies (NYSE:JEF) reiterated a “neutral” rating on American Axle & Manufacturing Holdings Inc (AXL). They now have a price target of $14.00 on the company.
Jefferies reiterated a “hold” rating on Boston Private Financial Holdings Incorporated (BPFH).
Wunderlich reiterated a “buy” rating on BTU International (BTUI).
Jefferies reiterated a “buy” rating on Celgene (CELG). They have a price target of $68.00 on the company.
Morgan Keegan reiterated a “market perform” rating on Alliance HealthCare Services, Inc. (AIQ).
Jefferies (NYSE:JEF) reiterated a “neutral” rating on American Axle & Manufacturing Holdings Inc (AXL). They now have a price target of $14.00 on the company.
Jefferies reiterated a “hold” rating on Boston Private Financial Holdings Incorporated (BPFH).
Wunderlich reiterated a “buy” rating on BTU International (BTUI).
Jefferies reiterated a “buy” rating on Celgene (CELG). They have a price target of $68.00 on the company.
Monday, January 31, 2011
Celgene (NASDAQ:CELG) Needs to Move Beyond Revlimid Dependence
With Revlimid accounting for just under 70 percent of Celgene (NASDAQ:CELG) sales, anything that causes sales to drop will result in a significant impact on the company, like slowing sales revealed in the last quarter.
Morgan Joseph says, "Following the company's 4Q10 earnings and conference call, we are more cautious about prospects for Celgene. While we like Revlimid's current growth and CELG's improving pipeline, we believe the key reason Celgene has been able to sustain a very good multiple on the stock is because of strong growth from Revlimid. Revlimid accounts for around 68% of sales and its contribution is expected to rise slightly over the next two years. While Revlimid sales grew at 44% in 2010, they have decelerated slightly since 2Q10, and based on current growth patterns (which are also consistent with management's current guidance), we now think sales will likely continue to decelerate into the end of 2011. By the end of 2011, we expect Revlimid growth to drop to the teens."
Morgan Joseph downgraded Celgene (CELG) from Buy to Hold. Celgene closed Friday at $51.18, falling $3.67, or 6.69 percent.
Morgan Joseph says, "Following the company's 4Q10 earnings and conference call, we are more cautious about prospects for Celgene. While we like Revlimid's current growth and CELG's improving pipeline, we believe the key reason Celgene has been able to sustain a very good multiple on the stock is because of strong growth from Revlimid. Revlimid accounts for around 68% of sales and its contribution is expected to rise slightly over the next two years. While Revlimid sales grew at 44% in 2010, they have decelerated slightly since 2Q10, and based on current growth patterns (which are also consistent with management's current guidance), we now think sales will likely continue to decelerate into the end of 2011. By the end of 2011, we expect Revlimid growth to drop to the teens."
Morgan Joseph downgraded Celgene (CELG) from Buy to Hold. Celgene closed Friday at $51.18, falling $3.67, or 6.69 percent.
Celgene (NASDAQ:CELG) Attractive on Revlimid Potential
Saying Revlimid maintenance could become the treatment of choice for front-line myeloma, Jefferies sees a strong future for Celgene (NASDAQ:CELG).
Even so, at current valuation, Jefferies believes it'll "require overall survival maturity of Revlimid maintenance trials, resolution of the Revlimid patent overhang, or success with earlier stage pipeline programs," to see major upside for the company.
Jefferies reiterates a "Buy" rating on Celgene, which closed Friday at $51.18, losing $3.67, or 6.69 percent. Jefferies lowered their price target on Celgene from $67 to $65.
Even so, at current valuation, Jefferies believes it'll "require overall survival maturity of Revlimid maintenance trials, resolution of the Revlimid patent overhang, or success with earlier stage pipeline programs," to see major upside for the company.
Jefferies reiterates a "Buy" rating on Celgene, which closed Friday at $51.18, losing $3.67, or 6.69 percent. Jefferies lowered their price target on Celgene from $67 to $65.
Subscribe to:
Posts (Atom)